Uva ursi

A small double-blind placebo-controlled trial (Larsson et al. 1993, n=57 women with recurrent cystitis) found zero UTI recurrences in the uva ursi group versus 23% recurrence in placebo over 12 months. A pharmacokinetic study (n=16) confirmed 65-67% urinary excretion of arbutin metabolites in humans, supporting the antimicrobial mechanism. The EMA and German Commission E approve short-term use for lower urinary tract infections based on traditional evidence.

In vitro studies demonstrate that arbutin is deconjugated by E. coli to release free hydroquinone with antimicrobial activity. A human pharmacokinetic study (n=16) confirmed substantial urinary excretion of hydroquinone and its conjugates after oral bearberry extract administration. However, a large RCT (ATAFUTI, n=382) found no significant benefit of uva ursi over placebo for acute uncomplicated UTI symptoms.

A series of Japanese pharmacological studies in animal models found that bearberry leaf extract and its constituent arbutin enhanced the anti-inflammatory and antiallergic effects of corticosteroids (prednisolone, dexamethasone, indomethacin) on immune-mediated inflammation, including contact dermatitis and carrageenin-induced paw edema models.

A rat study found that aqueous extract of Arctostaphylos uva-ursi increased urine flow, though without significantly increasing urinary sodium excretion, suggesting a mild diuretic mechanism distinct from typical saluretic agents.

In vitro studies show that bearberry extract and isolated arbutin inhibit tyrosinase activity and melanin production from both dopa and dopachrome substrates. Multiple active constituents were identified including arbutin, gallic acid, and tannins.

In vitro studies demonstrate strong radical scavenging capacity of bearberry leaf extract (90.4 mmol Trolox equivalents/g dry weight by ABTS assay), with ability to retard lipid oxidation in model food systems. Phytochemical profiling confirms high phenolic acid and tannin content contributing to antioxidant properties.